CADL
Candel Therapeutics, Inc.Company Information
- Company Name
- Candel Therapeutics, Inc.
- CIK
- CIK0001841387
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CADL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CADL
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-02-23
- Last sale
- 2026-09-11
- Shares purchased (TTM)
- 550,458
- Shares sold (TTM)
- 96,826
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 50,743,537
- Shares outstanding
- 74,131,229
- Ownership
- 68.45%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 8.31%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 202 | 195 | 120 | 87 | 101 | 92 | 103 | 17 | 21 | 26 | 35 | 43 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 3 | 2 | 3 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | ||||||
| Assets Current | 204 | 198 | 121 | 90 | 104 | 93 | 104 | 18 | 23 | 27 | 37 | 45 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | ||||||
| Operating Lease Right Of Use Asset | 1 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 208 | 202 | 125 | 94 | 106 | 96 | 107 | 22 | 26 | 31 | 41 | 50 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 3 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 7 | 3 | 7 | 5 | 4 | 3 | 5 | 5 | 3 | 3 | 4 | 3 | ||||||
| Long Term Debt Current | - | - | 0 | 4 | 7 | 9 | 10 | 10 | 10 | 10 | 9 | 6 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | 0 | ||||||
| Liabilities Current | 13 | 7 | 9 | 11 | 15 | 20 | 38 | 15 | 14 | 14 | 14 | 10 | ||||||
| Deferred Revenue Noncurrent | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | 0 | ||||||
| Long Term Loans From Bank | 47 | 46 | 46 | 0 | 0 | 0 | 2 | 4 | 7 | 9 | 12 | 14 | ||||||
| Other Long Term Debt Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 82 | 64 | 73 | 13 | 16 | 21 | 41 | 37 | 36 | 25 | 28 | 27 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Additional Paid In Capital Common Stock | 404 | 377 | 282 | 281 | 280 | 259 | 259 | 163 | 158 | 151 | 150 | 149 | ||||||
| Retained Earnings Accumulated Deficit | -278 | -239 | -230 | -201 | -190 | -185 | -192 | -178 | -167 | -145 | -137 | -126 | ||||||
| Stockholders Equity | 126 | 138 | 52 | 80 | 90 | 75 | 66 | -15 | -10 | 6 | 13 | 23 | ||||||
| Liabilities And Stockholders Equity | 208 | 202 | 125 | 94 | 106 | 96 | 107 | 22 | 26 | 31 | 41 | 50 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 76 | 73 | 55 | 55 | 55 | 49 | 47 | 32 | 31 | 29 | 29 | 29 | ||||||
| Shares Outstanding | 76 | 73 | 55 | 55 | 55 | 49 | 47 | 32 | 31 | 29 | 29 | 29 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCandel Therapeutics, Inc. (CADL) — SEC Financial Statements & Analysis
Candel Therapeutics, Inc. (CADL) is a biological products, (no diagnostic substances) company, incorporated in DE. Candel Therapeutics, Inc. trades on Nasdaq as: CADL. Candel Therapeutics, Inc. (CADL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Candel Therapeutics, Inc. carries a market cap of $763.55M, a P/E ratio of -8.62x, a P/B ratio of 6.05x, a P/S ratio of 831.44x, an enterprise value of $561.57M, and an EV/EBITDA multiple of -7.88x. On profitability, it posts an operating margin of -113046.88%, a net margin of -99771.88%, a Return on Equity (ROE) of -81.84%, a Return on Assets (ROA) of -56.37%, and a Return on Invested Capital (ROIC) of -280.62%. Per share, it reports EPS of $-1.19, diluted EPS of $-1.19, free cash flow per share of $-0.77, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 299.94% year-over-year, and EPS growth of 177.79% year-over-year. On the balance sheet, it maintains a current ratio of 16.09x, a quick ratio of 15.89x, working capital of $191.47M, a debt-to-equity ratio of 0.65x, a debt ratio of 0.39, an interest coverage ratio of -15.26x, free cash flow of $-57.32M (TTM), and net debt of $-201.98M. Figures sourced from SEC EDGAR.
- Market Cap
- $763.55M
- P/E TTM
- -8.62x
- EPS TTM
- $-1.19
- P/B TTM
- 6.05x
- ROE TTM
- -81.84%
- ROA TTM
- -56.37%
- Debt To Equity
- 0.65x
- Free Cash Flow TTM
- $-57.32M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Candel Therapeutics, Inc. in?
Candel Therapeutics, Inc. (CADL) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CADL trade on?
Candel Therapeutics, Inc. (CADL) trades on the Nasdaq.
Where is Candel Therapeutics, Inc. incorporated?
Candel Therapeutics, Inc. is incorporated in DE.
When was Candel Therapeutics, Inc. (CADL)'s most recent SEC filing?
Candel Therapeutics, Inc. (CADL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CADL's market cap?
Candel Therapeutics, Inc. (CADL) has a market capitalization of $763.55M as of 2026-06-30.
What is CADL's EPS (earnings per share)?
Candel Therapeutics, Inc. (CADL)'s trailing twelve month EPS is $-1.19 as of 2026-06-30.
What is CADL's ROE (return on equity)?
Candel Therapeutics, Inc. (CADL)'s trailing twelve month Return on Equity (ROE) is -81.84% as of 2026-06-30.
What is CADL's ROA (return on assets)?
Candel Therapeutics, Inc. (CADL)'s trailing twelve month Return on Assets (ROA) is -56.37% as of 2026-06-30.
What is CADL's ROIC (return on invested capital)?
Candel Therapeutics, Inc. (CADL)'s trailing twelve month Return on Invested Capital (ROIC) is -280.62% as of 2024-12-31.
What is CADL's EV/EBITDA?
Candel Therapeutics, Inc. (CADL)'s trailing twelve month EV/EBITDA is -7.88x as of 2026-06-30.